History of Tachykinin Receptors
The rapid advances in molecular pharmacology in recent years have made the concept of multiple receptors and receptor subtypes for neurotransmitters and neuropeptides a commonplace. We are no longer surprised to learn that on closer examination the muscarinic receptor exists in five distinct molecular forms, encoded by separate genes (Hulme et al., 1990), or that the dopamine receptor similarly has five subtypes, some of which in turn exist in a variety of isoforms because of variable mRNA splicing (Iversen, 1992), or the existence of genetically determined minor variants (Van Tol et al., 1992). That the varied biological actions of the three mammalian tachykinins should be mediated by three different receptors is thus easily accepted—indeed, one would anticipate that such a complex family of related neuropeptides might be associated with a larger number of receptor subtypes.
KeywordsDopamine Atropine Inositol Guanine Lactam
Unable to display preview. Download preview PDF.
- Appell, K. C., Fragale, B. J., Losgig, J., Singh, S., and Tomczuk, B. E. (1992) Antagonists that demonstrate species differences in neurokinin-1 receptors.Mol. Pharmacol. 11, 774–778.Google Scholar
- Burcher, E., Buck, S. H., Lovenberg, W., and 0’ Donohue T. L. (1986) Characterization and autoradiographic localization of multiple tachykinin binding sites in gastrointestinal tract and bladder.J. Pharm. Exp. Ther. 236, 819–831.Google Scholar
- Cascieri, M. A., Chicchi, G. G., Freidinger, R. M., Dylion Colton, C., Perlow, D. S., Williams, B., Curtis, N. R., McKnight, A. T., Maguire, J. J., Veber, D. F., and Liang, T. (1986) Conformationally constrained tachykinin analogs which are selective ligands for the eledoisin binding site.Mol. Pharmacol. 29, 34–38.PubMedGoogle Scholar
- Couture, R. and Regoli D. (1982) Mini review: smooth muscle pharmacology of substanceP. Pharmacology 24, 1–25.Google Scholar
- Garret, C., Carruette, A., Fardin, V., Moussaoui, S., Peyronel, J.-F., Blanchard, J.-C., and Laduron, P.M. (1991) Pharmacological properties of a potent and selective nonpeptide substance P antagonist.Proc. Natl. Acad. Sci. USA88,10,208–10, 212.Google Scholar
- McKnight, A. T., Maguire, J. J., Elliott, N.J., Fletcher, A. E., Foster, A. C., Tridgett, R., Williams, B. J., Longmore, J., and Iversen, L. L. (1991) Pharmacological specificity of novel, synthetic, cyclic peptides as antagonists at tachykinin receptors.Br. J. Pharmacol. 104, 355–360.PubMedCrossRefGoogle Scholar
- Petitet, F., Beaujouan, J.-C., Saffroy, M., Torrens, Y., Chassaing, G., Lavielle, S., Besseyre, J., Garret, C., Curruette, A., and Glowinski, J. (1991) Further demonstration that [Pro9]-substance Pis a potent and selective ligand of NK-1 tachykinin receptors.J. Neurochem. 56, 879–889.PubMedCrossRefGoogle Scholar
- Torrens, Y., Lavielle, S., Chassaing, G., Marquet, A., Glowinski, J., and Beaujouan, J. C. (1984) Neuromedin K, a tool to further distinguish two central tachykinin binding sites.Eur. J. Pharmacol. 102, 381,382.Google Scholar